Dongmei Lin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2587627/publications.pdf

Version: 2024-02-01

42 papers	1,367 citations	567281 15 h-index	361022 35 g-index
47 all docs	47 docs citations	47 times ranked	2369 citing authors

#	Article	IF	Citations
1	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
2	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
3	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
4	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 3701-3709.	1.6	129
5	Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nature Genetics, 2013, 45, 632-638.	21.4	97
6	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	2.0	58
7	Prognostic value of <scp>PD</scp>â€L1 expression in combination with <scp>CD</scp>8⁺<scp>TIL</scp>s density in patients with surgically resected nonâ€small cell lung cancer. Cancer Medicine, 2018, 7, 32-45.	2.8	48
8	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagnostic Pathology, 2018, 13, 30.	2.0	43
9	Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers. Pathology and Oncology Research, 2020, 26, 2577-2585.	1.9	30
10	Primary Tumor Location Is a Useful Predictor for Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma. Clinical Lung Cancer, 2017, 18, e49-e55.	2.6	28
11	Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Modern Pathology, 2022, 35, 403-411.	5.5	28
12	PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagnostic Pathology, 2017, 12, 72.	2.0	25
13	Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget, 2016, 7, 64410-64420.	1.8	21
14	Chinese multidisciplinary expert consensus: Guidelines on percutaneous transthoracic needle biopsy. Thoracic Cancer, 2018, 9, 1530-1543.	1.9	17
15	A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. Cancer Management and Research, 2018, Volume 10, 115-121.	1.9	16
16	CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. International Journal of Hematology, 2018, 108, 254-266.	1.6	14
17	The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. Cancer Biology and Medicine, 2019, 16, 811-821.	3.0	14
18	Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. Human Pathology, 2018, 81, 261-271.	2.0	13

#	Article	IF	Citations
19	Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas. Endocrine Pathology, 2020, 31, 39-45.	9.0	13
20	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
21	Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Modern Pathology, 2021, 34, 1990-1998.	5.5	13
22	Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Diagnostic Pathology, 2021, 16, 38.	2.0	12
23	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. Lung Cancer, 2019, 130, 135-142.	2.0	10
24	Updates in the advances of sporadic medullary thyroid carcinoma: from the molecules to the clinic. Gland Surgery, 2020, 9, 1847-1856.	1.1	10
25	Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer. Oncotarget, 2016, 7, 52862-52869.	1.8	9
26	Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer. Modern Pathology, 2022, 35, 218-227.	5.5	8
27	Feasibility of using <scp>P16</scp> methylation as a cytologic marker for esophageal squamous cell carcinoma screening: A pilot study. Cancer Medicine, 2022, 11, 4033-4042.	2.8	8
28	Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Journal of Cancer Research and Clinical Oncology, 2020, 146, 407-416.	2.5	7
29	Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1079-1083.	2.8	7
30	A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Nonâ˜Small Cell Lung Cancer. Advances in Anatomic Pathology, 2021, 28, 439-445.	4.3	7
31	Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. Journal of Translational Medicine, 2022, 20, 114.	4.4	7
32	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. Journal of Cancer, 2021, 12, 7390-7398.	2.5	6
33	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in <scp> KRAS </scp> â€mutant invasive nonâ€mucinous adenocarcinoma. Thoracic Cancer, 2022, 13, 1050-1058.	1.9	5
34	Neoadjuvant <scp>PD</scp>â€1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung. Thoracic Cancer, 2022, 13, 442-452.	1.9	4
35	Estimation of the Survival of Patients With Lung Squamous Cell Carcinoma Using Genomic Copy Number Aberrations. Clinical Lung Cancer, 2016, 17, 68-74.e5.	2.6	3
36	Percentage of Newly Proposed High-Grade Patterns Is Associated with Prognosis of Pathological T1-2N0M0 Lung Adenocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	3

#	Article	IF	Citations
37	Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry. Journal of Clinical Pathology, 2022, 75, 452-458.	2.0	2
38	Evaluation of the Impact of Intratumoral Heterogeneity of Esophageal Cancer on Pathological Diagnosis and P16 Methylation and the Representativity of Endoscopic Biopsy. Frontiers in Oncology, 2021, 11, 683876.	2.8	2
39	Synchronous and metachronous metastasis to renal parenchyma of esophageal squamous cell carcinoma: two case reports and review of the literature. Translational Cancer Research, 2021, 10, 1135-1143.	1.0	0
40	Co-occurring genetic alterations and primary EGFR T790M mutations detected by next-generation sequencing in pre-TKI treated patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e13128-e13128.	1.6	0
41	ASO Author Reflections: High Percentage of Newly Proposed High-Grade Patterns (Micropapillary,) Tj ETQq1 1 0.784314 rgBT /Overlo Adenocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
42	ASO Visual Abstract: Percentage of Newly Proposed High-Grade Patterns Is Associated With Prognosis of Pathologic T1-2N0M0 Lung Adenocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0